Ciencia

Abstract
Background
The prevalence of osteoporosis is estimated to be 4.8% in Hispanic men (95%CI, 3%-6%). Data on prevalence in Asian-American men and other ethnic groups are lacking, but isestimated to be 7% in white men, 5% in black men.
With the aging of the population, rates of osteoporosis in men are expected to increase nearly 50% in the next 15 years, and hip fractures rates areprojected to double or triple by 2040.
Although osteoporosis is often viewed as a disease of women, Male osteoporosis is an important public health problem, because is substantially underdiagnosed,undertreated, and underreported and inadequately researched; furthermore studies show the disease – osteoporosis- in the majority of men, result in substantial morbidity-mortality, because osteoporoticfractures present more secondary complications than women, with a mortality rate of 37.5 % within one year of facture and financial expenses in men. Identifying men at risk for low BMD and fracture canhelp clinicians determine which men should be tested.
The Male Osteoporosis Risk Estimation Score (MORES), is a simple approach to identify men at risk for osteoporosis that uses age, weight, and ahistory of chronic obstructive pulmonary disorder, was developed and validated previously to identify male osteoporosis risk who might benefit from bone densitometry.

This study evaluated theprevalence of osteoporosis and the effectiveness of the MORES in our population to identify men at risk for osteoporosis for a clinical prediction tool and refer them for confirmatory DXA scans.Purpose
To determine the prevalence of male osteoporosis and validate a clinical prediction rule, the male osteoporosis risk estimation score (MORES), and subsequent who might benefit from dual-energyx-ray absorptiometry (DXA).
Methods
We performed a descriptive, prospective and transversal survey, including all asymptomatic males older than 40 years, in a group of male outpatients assisting to...